Mankind Pharma Ltd (MANKIND) — Capital Reinvestment Ratio
Latest as of March 2023:
0.28x
Mankind Pharma Ltd (MANKIND) has a Capital Reinvestment Ratio of 0.28x as of March 2023, meaning it reinvests 0% of its operating cash flow (Rs4.84 Billion) in capital expenditures (Rs1.33 Billion). See Mankind Pharma Ltd free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.28x
Capex / Operating Cash Flow
Operating Cash Flow
Rs4.84 Billion
INR
Capital Expenditures
Rs1.33 Billion
INR
Data as of
Mar 2023
Most recent filing
Mankind Pharma Ltd Capital Reinvestment Ratio (2019–2025)
This chart tracks Mankind Pharma Ltd's Capital Reinvestment Ratio across 7 annual periods.
Annual Capital Reinvestment Ratio for Mankind Pharma Ltd (2019–2025)
Year-by-year Capital Reinvestment Ratio for Mankind Pharma Ltd from 2019 to 2025. For live market cap and broader valuation context, see Mankind Pharma Ltd (MANKIND) market capitalisation.
| Year | Reinvestment Ratio | Operating CF (INR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.19x | Rs24.13 Billion | Rs4.61 Billion | ▲ +7.5% |
| 2024 | 0.18x | Rs21.52 Billion | Rs3.82 Billion | ▼ -61.3% |
| 2023 | 0.46x | Rs18.13 Billion | Rs8.32 Billion | ▼ -82.0% |
| 2022 | 2.55x | Rs9.20 Billion | Rs23.46 Billion | ▲ +828.6% |
| 2021 | 0.27x | Rs11.37 Billion | Rs3.12 Billion | ▲ +28.9% |
| 2020 | 0.21x | Rs10.70 Billion | Rs2.28 Billion | ▼ -57.0% |
| 2019 | 0.50x | Rs6.00 Billion | Rs2.98 Billion | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow